UK-based life science investor Syncona has launched a new company – Slingshot Therapeutics – with a mission to find promising projects in academia and translate them into full-blown develop
UK-headquartered Beacon Therapeutics has raised a whopping $170 million in second-round financing that will be used to advance a gene therapy for an inherited cause of blindness through a p
UK life sciences investor Syncona is bankrolling a new gene therapy company, Beacon Therapeutics, that emerged this morning with a pipeline headed by a therapy acquired fr
The healthcare company Syncona Limited has announced its newly established portfolio company is to acquire all outstanding shares of Applied Genetic Technologies Corporation (AGTC), a clini
OMass Therapeutics has raised an impressive $100 million in a Series B financing that is said to be the largest ever for a UK biotech focusing on small-molecule drug development.